AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn., July 08, 2025--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback